Receptor crosstalk. Implications for cardiovascular function, disease and therapy

European Journal of Biochemistry

Volumn 269, Issue 19, 2002, Pages 4713-4730

  Dzimiri, Nduna ^a,b  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^b Research Centre MBC 03   (Saudi Arabia)

Author keywords

Contractile function; G proteins; Heart; Heart failure; Hypertension; Hypertrophy; Receptor crosstalk; Regulatory systems; Signal transduction; Subcellular; Vasculature

Indexed keywords

ADENOSINE; ADRENALIN; ADRENERGIC RECEPTOR; ALDOSTERONE ANTAGONIST; ALDOSTERONE RECEPTOR; ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BETA 1 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN; G PROTEIN COUPLED RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; HEART RECEPTOR; ION CHANNEL; ISOPRENALINE; NATRIURETIC FACTOR; NORADRENALIN; OPIATE RECEPTOR; PHOSPHODIESTERASE INHIBITOR; PROTEIN KINASE; RECEPTOR SUBTYPE;

ADAPTATION; ADRENERGIC SYSTEM; BLOOD PRESSURE REGULATION; BLOOD VOLUME; CARDIOVASCULAR DISEASE; CARDIOVASCULAR FUNCTION; CIRCULATION; CONGESTIVE HEART FAILURE; ENZYME ACTIVATION; HEART CONTRACTION; HEART SUPRAVENTRICULAR ARRHYTHMIA; HUMAN; NONHUMAN; NORADRENERGIC SYSTEM; PHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN FUNCTION; REGULATORY MECHANISM; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SECOND MESSENGER; SIGNAL TRANSDUCTION;

ADAPTATION, PHYSIOLOGICAL; ANIMALS; CARDIOVASCULAR DISEASES; CARDIOVASCULAR PHYSIOLOGY; CORONARY CIRCULATION; GTP-BINDING PROTEINS; HUMANS; MODELS, CARDIOVASCULAR; MYOCARDIAL CONTRACTION; RECEPTOR CROSS-TALK; RECEPTORS, ADRENERGIC; SIGNAL TRANSDUCTION;

EID: 0036399259     PISSN: 00142956     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1432-1033.2002.03181.x     Document Type: Review

References (106)

1. Dzimiri, N. (1999) Regulation of β-adrenoceptor signaling in cardiac function and disease. Pharmacol. Rev. 51, 465-502.
2. Bylund, D.B., Bond, R.A., Clarke, D.E., Eikelberg, D.C., Hieble, J.P., Langer, S.Z., Lefkowitz, R.J., Minneman, K.P., Molinoff, P.B., Ruffolo, R.R., Strossberg, A.D. & Trendelenburg, U.G. (1998) Adrenoceptors. In The IUPHAR Compendium of Receptor Characterization and Classification (Girdlestone, D., ed.), pp. 58-74. IUPHAR Media, London.
3. Birdsall, N.J.M., Buckley, N.J., Caulfield, M.P., Hammer, R., Kilbinger, H.J., Lambrecht, G., Mutchler, E., Nathanson, N.M. & Schwarz, R.D. (1998) Muscarinic acetylcholine receptors. In The IUPHAR Compendium of Receptor Characterization and Classification (Girdlestone, D., ed.), pp. 36-45. IUPHAR Media, London.
4. De Gasparo, M., Catt, K.J., Inagami, T., Wright, J.W. & Unger, T. (2000) The angiotensin II receptors. Internat. Union Pharmacol. XXIII. 52, 415-472.
5. Silberbach, M. & Roberts, C.T. Jr (2001) Natriuretic peptide signalling: molecular and cellular pathways to growth regulation. Cell Signal. 13, 221-231.
6. Antunes-Rodrigues, J., Marubayashi, U., Favaretto, A.L., Gutkowska, J. & McCann, S.M. (1993) Essential role of hypothalamic muscarinic and α-adrenergic receptors in atrial natriuretic peptide release induced by blood volume expansion. Proc. Natl Acad. Sci. USA 90, 10240-10244.
7. Fredholm, B.B., Ijzerman, A.P., Jacobson, K.A., Linden, J. & Stiles, G.L. (1998) Adenosine receptors. In The IUPHAR Compendium of Receptor Characterization and Classification (Girdlestone, D., ed.), pp. 48-57. IUPHAR Media, London.
8. Schiffrin, E.L. & Touyz, R.M. (1998) Vascular biology of endothelin. J. Cardiovasc. Pharmacol. 32, S2-S13.
9. Dhawan, N.B., Raghbur, R. & Hamon, M. (1998) Opioid receptors. In The IUPHAR Compendium of Receptor Characterization and Classification (Girdlestone, D., ed.), pp. 218-226. IUPHAR Media, London.
10. 1-Adrenoceptor-mediated inhibition of cellular cAMP accumulation in neonatal rat ventricular myocytes. Naunyn Schmiedebergs Arch. Pharmacol. 347, 384-393.
11. 1- and β-adrenoceptors. Circulation 95, 1260-1268.
12. Rapacciuolo, A., Esposito, G., Caron, K., Mao, L., Thomas, S.A. & Rockman, H.A. (2001) Important role of endogenous norepinephrine and epinephrine in the development of in vivo pressure-overload cardiac hypertrophy. J. Am. Coll. Cardiol. 38, 876-832.
13. 1B-AR regulates β-AR activity via molecular crosstalk. J. Mol. Cell. Cardiol. 30, 1827-1839.
14. 1-adrenergic receptor-mediated regulation of β-adrenergic signaling. J. Biol. Chem. 272, 21253-21259.
15. Morisco, C., Zebrowski, D., Condorelli, G., Tsichlis, P., Vatner, S.F. & Sadoshima, J. (2000) The Akt-glycogen synthase kinase 3β pathway regulates transcription of atrial natriuretic factor induced by β-adrenergic receptor stimulation in cardiac myocytes. J. Biol. Chem. 275, 14466-14475.
16. Sprenkle, A.B., Murray, S.F. & Glembotski, C.C. (1995) Involvement of multiple cis elements in basal- α-adrenergic agonist-inducible atrial natriuretic factor transcription - roles for serum response element and an SP-1-like element. Circ. Res. 77, 1060-1069.
17. 1a-adrenergic receptor subtype mRNA and density in neonatal rat cardiac myocytes. Circ. Res. 81, 396-403.
18. 1b-adrenoreceptors in rat-1 fibroblasts. J. Biol. Chem. 272, 27330-27337.
19. 2-adrenergic receptors in rabbit cerebral arteries. Br. J. Pharmacol. 125, 1188-1193.
20. Wu-Wong, J.R. & Opgenorth, T.J. (1998) Endothelin and isoproterenol counter-regulate cAMP and mitogen-activated protein kinases. J. Cardiovasc. Pharmacol. 31, S185-S191.
21. Tseng, C.J., Chan, J.Y., Lo, W.C. & Jan, C.R. (2001) Modulation of catecholamine release by endogenous adenosine in the rat adrenal medulla. J. Biomed. Sci. 8, 389-394.
22. 2a receptor activation in rat heart. Am. J. Physiol. 276, H341-H349.
23. Gelband, C.H., Sumners, C., Lu, D. & Raizada, M.K. (1998) Angiotensin receptors and norepinephrine neuromodulation: implications of functional coupling. Regulat. Peptide. 73, 141-147.
24. 1-adrenergic receptor responsiveness in rat heart. J. Cardiovasc. Pharmacol. 29, 257-264.
25. Henegar, J.R., Schwartz, D.D. & Janicki, J.S. (1998) ANG II-related myocardial damage, role of cardiac sympathetic catecholamines and β-receptor regulation. Am. J. Physiol. 275, H534-H541.
26. Gyurko, R., Kuhlencordt, P., Fishman, M.C. & Huang, P.L. (2000) Modulation of mouse cardiac function in vivo by eNOS and ANP. Am. J. Physiol. 278, H971-H981.
27. Calderone, A., Thaik, C.M., Takahashi, N., Chang, D.L.F. & Colucci, W.S. (1998) Nitric oxide, atrial natriuretic peptide, cyclic GMP inhibit the growth-promoting effects of norepinephrine in cardiac myocytes and fibroblasts. J. Clin. Invest. 101, 812-818.
28. Hare, J.M. & Colucci, W.S. (1995) Role of nitric oxide in the regulation of myocardial function. Progr. Cardiovasc. Dis. 38, 155-166.
29. Pepe, S., Xiao, R.P., Hohl, C., Altschuld, R. & Lakatta, E.G. (1997) 'Cross talk' between opioid peptide and adrenergic receptor signaling in isolated rat heart. Circulation 95, 2122-2129.
30. Yu, X.C., Li, H.Y., Wang, H.X. & Wong, T.M. (1998) U50,488H inhibits effects of norepinephrine in rat cardiomyocytes - cross talk between κ-opioid and β-adrenergic receptors. J. Mol. Cell. Cardiol. 30, 405-413.
31. Yu, X.C.,Wang, H.X.,Zhang, W.M. & Wong, T.M. (1999) Cross-talk between cardiac κ-opioid and β-adrenergic receptors in developing hypertensive rats. J. Mol. Cell. Cardiol. 31, 597-605.
32. Soualmia, H., Barthelemy, C., Masson, F., Maistre, G., Eurin, J. & Carayon, A. (1997) Angiotensin II-induced phosphoinositide production and atrial natriuretic peptide release in rat atrial tissue. J. Cardiovasc. Pharmacol. 29, 605-611.
33. Palaparti, A. & Anand-Srivastava, M.B. (1998) Angiotensin II modulates ANP-R2/ANP-C receptor-mediated inhibition of adenylyl cyclase in vascular smooth muscle cells: Role of protein kinase 2. J. Mol. Cell. Cardiol. 30, 1471-1582.
34. Katoh, M., Egashira, K., Usui, M., Ichiki, T., Tomita, H., Shimokawa, H., Rakugi, H. & Takeshita, A. (1998) Cardiac angiotensin II receptors are upregulated by long-term inhibition of nitric oxide synthesis in rats. Circ. Res. 83, 743-751.
35. Ferri, C., Desideri, G.M., Baldoncini, R., Bellini, C., Valenti, M., Santucci, A. & De Mattia, G. (1999) Angiotensin II induces the release of endothelin-1 from human cultured endothelial cells but does not regulate its circulating levels. Clin. Sci. 96, 261-270.
36. Wada, A., Tsutamoto, T., Maeda, Y., Kanamori, T., Matsuda, Y. & Kinoshita, M. (1996) Endogenous atrial natriuretic peptide inhibits endothelin-1 in dogs with severe congestive heart failure. Am. J. Physiol. 39, H1819-H1824.
37. A receptor regulates signaling and ANF gene expression via multiple G protein-linked pathways. Am. J. Physiol. 272, H130-H137.
38. - current. Am. J. Physiol. 273, H2539-H2548.
39. 1-adrenergic inhibition of the β-adrenergically activated chloride current in cardiac myocytes. Mol. Pharmacol. 51, 853-860.
40. +channels and sodium pump in the vasodilation induced by acetylcholine, nitric oxide, cyclic GMP in the rabbit aorta. General Pharmacol. 33, 35-41.
41. Hurowitz, E.H., Melnyk, J.M., Chen, Y.J., Kouros-Mehr, H., Simon, M.I. & Shizuya, H. (2000) Genomic characterization of the human heterotrimeric G protein α, β, and γ subunit genes. DNA Res. 7, 111-120.
42. Sunahara, R., Dessauer, C.W. & Gilman, A.G. (1996) Complexity and diversity of mammalian adenylyl cyclases. Annu. Rev. Pharmacol. Toxicol. 36, 461-480.
43. 2-adrenergic receptor to different G proteins by protein kinase A. Nature 390, 88-91.
44. Daaka, Y., Luttrell, L.M., Ahn, S., Della Rocca, G.J., Ferguson, S.S., Caron, M.G. & Lefkowitz, R.J. (1998) Essential role for G protein-coupled receptor endocytosis in the activation of mitogen-activated protein kinase. J. Biol. Chem. 273, 685-688.
45. +channel in the heart - modal regulation by G protein βγ subunits. J. General Physiol. 112, 199-210.
46. Gutkind, J.S. (1998) The pathways connecting G protein-coupled receptors to the nucleus through divergent mitogen-activated protein kinase cascades. J. Biol. Chem. 273, 1839-1842.
47. βγ subunits mediate Src-dependent phosphorylation of the epidermal growth factor receptor. A scaffold for G protein-coupled receptor-mediated Ras activation. J. Biol. Chem. 272, 4637-4644.
48. Katada, T., Kurosu, H., Okada, T., Suzuki, T., Tsujimoto, N., Tagasuga, S., Kontani, K., Hazeki, O. & Ui, M. (1999) Synergistic activation of a family of phosphoinositide 3-kinase via G-protein coupled and tyrosine kinase-related receptors. Chem. Phys. Lipids 98, 79-86.
49. 3-kinase gamma. Science 275, 394-397.
50. De Bold, A.J., Ma, K.K., Zhang, Y., de Bold, M.L., Bensimon, M. & Khoshbaten, A. (2001) The physiological and pathophysiological modulation of the endocrine function of the heart. Can. J. Physiol. Pharmacol. 79, 705-714.
51. De Bold, A.J., Bruneau, B.G. & de Bold, K.M.L. (1996) Mechanical and neuroendocrine regulation of the endocrine heart. Cardiovasc. Res. 31, 7-18.
52. Buccafusco, J. (1996) The role of central cholinergic neurons in the regulation of blood pressure and in experimental hypertension. Pharmacol. Rev. 48, 179-211.
53. Rossi, G.P., Seccia, T.M. & Nussdorfer, G.G. (2001) Reciprocal regulation of endothelin-1 and nitric oxide: relevance in the physiology and pathology of the cardiovascular system. Int. Rev. Cytol. 209, 241-272.
54. Endoh, M. (1995) The effects of various drugs on the myocardial inotropic response. General Pharmacol. 26, 1-31.
55. i proteins. Sci. STKE. 104, 1-10.
56. Yu, H.J., Ma, H. & Green, R.D. (1993) Calcium entry via L-type calcium channels acts as a negative regulator of adenylyl cyclase activity and cyclic AMP levels in cardiac myocytes. Mol. Pharmacol. 44, 689-693.
57. Schillace, R.V. & Scott, J.D. (1999) Association of the type 1 protein phosphatase PP1 with the A-kinase anchoring protein AKAP220. Curr. Biol. 9, 321-324.
58. q-coupled receptors is mediated by Gβγ exchange. Proc. Natl Acad. Sci. USA 96, 10626-10631.
59. Wenzel, R.R., Ruthemann, J., Bruck, H., Schafers, R.F., Michel, M.C. & Philipp, T. (2001) Endothelin-A receptor antagonist inhibits angiotensin II and noradrenaline in man. Br. J. Clin. Pharmacol. 52, 151-157.
60. Piano, M.R., Bondmass, M. & Schwertz, D.W. (1998) The molecular and cellular pathophysiology of heart failure. Heart Lung 27, 3-19.
61. 2-adrenergic signaling in adult mouse cardiac myocytes. Proc. Natl Acad. Sci. USA 98, 1607-1612.
62. Sack, M.N. & Kelly, D.P. (1998) The energy substrate switch during development of heart failure: Gene regulatory mechanisms. Internat. J. Mol. Med. 1, 17-24.
63. Lefkowitz, R.J. (1998) G protein-coupled receptors. III. New roles for receptor kinases and β-arrestins in receptor signaling and desensitization. J. Biol. Chem. 273, 18677-18680.
64. Yatani, A., Imai, N., Himura, Y., Suematsu, M. & Liang, C.S. (1997) Chronic opiate-receptor inhibition in experimental congestive heart failure in dogs. Am. J. Physiol. 272, H478-H484.
65. Hare, J.M., Givertz, M.M., Creager, M.A. & Colucci, W.S. (1998) Increased sensitivity to nitric oxide synthase inhibition in patients with heart failure: potentiation of β-adrenergic inotropic responsiveness. Circulation 97, 161-166.
66. Sulakhe, P.V., Vo, X.T. & Mainra, R.R. (1997) Differential nature of cross-talk among three G-coupled receptors regulating adenylyl cyclase in rat cardiomyocytes chronically exposed to receptor agonists. Mol. Cell. Biochem. 176, 75-82.
67. Dzimiri, N., Moorji, A., Kumar, M., Kumar, N. & Halees, Z. (1996) Comparison of the effect of left ventricular Volume and pressure overload on β-adrenoceptor density in left heart valvular disease. Internat. J. Cardiol. 53, 109-116.
68. 2-adrenoceptor signalling in patients with left ventricular Volume overload disease. Clin. Exp. Pharm. Physiol. 29, 181-188.
69. Dzimiri, N., Moorji, A., Kumar, M., Bakr, S., Kumar, N., Almotrefi, A.A. & Halees, Z. (1996) Effect of left ventricular pressure and Volume overload on α-adrenoceptor activity in patients with rheumatic heart valvular disease. General Pharmacol. 27, 539-543.
70. Fukai, D., Wada, A., Tsutamoto, T. & Kinoshita, M. (1998) Short-term and long-term inhibition of endogenous atrial natriuretic peptide in dogs with early-stage heart failure. Jpn. Circ. J. 62, 604-610.
71. Kohno, M.K., Yokokawa, K., Horio, T., Yasunari, K., Murakawa, K. & Takeda, T. (1992) Atrial and brain natriuretic peptides inhibit the endothelin-1 secretory response to angiotensin II in porcine aorta. Circ. Res. 70, 241-247.
72. Farmer, J.A. & Torre-Amione, G. (2001) The renin angiotensin system as a risk factor for coronary artery disease. Curr. Atheroscler. Report 3, 117-124.
73. Dashwood, M.R. & Tsui, J.C. (2002) Endothelin-1 and atherosclerosis: potential complications associated with endothelin-receptor blockade. Atherosclerosis 160, 297-304.
74. Kloner, R.A. & Jennings, R.B. (2001) Consequences of brief ischemia: stunning, preconditioning, and their clinical implications: part 1. Circulation 104, 2981-2899.
75. Yamaguchi, F., Nasa, Y., Yabe, K., Ohba, S., Hashizume, Y., Ohaku, H., Furuhama, K. & Takeo, S. (1997) Activation of cardiac muscarinic receptor and ischemic preconditioning effects in in situ rat heart. Heart Vessels 12, 74-83.
76. Gajewski, M., Moutiris, J.A., Maslinski, S. & Ryzewski, J. (1995) The neuromodulation aspects of ischaemic myocardium: the importance of cholinergic system. J. Physiol. Pharmacol. 46, 107-125.
77. Mubagwa, K. & Flameng, W. (2001) Adenosine, adenosine receptors and myocardial protection: an updated overview. Cardiovasc. Res. 52, 25-39.
78. Bolli, R. (2001) Cardioprotective function of inducible nitric oxide synthase and role of nitric oxide in myocardial ischemia and preconditioning: an overview of a decade of research. J. Mol. Cell. Cardiol. 33, 1897-1918.
79. i/o proteins are involved in adenosine- and ischemic preconditioning-mediated renal protection. J. Am. Soc. Nephrol. 12, 233-240.
80. ATP channels, and protein kinase C during cardiocyte apoptosis. J. Mol. Cell. Cardiol. 33, 2007-2014.
81. Yamazaki, T. & Yazaki, Y. (2000) Molecular basis of cardiac hypertrophy. Zeitschr. Kardiol. 89, 1-6.
82. Kim, S. & Iwao, H. (1999) Activation of mitogen-activated protein kinases in cardiovascular hypertrophy and remodeling. Jpn. J. Pharmacol. 80, 97-102.
83. 1B-adrenoceptors in neonatal rat myocardium: implications in cardiac hypertrophy. J. Pharmacol. Exp. Ther. 286, 489-496.
84. Eskildsen-Helmond, Y.E., Bezstarosti, K., Dekkers, D.H., van Heugten, H.A. & Lamers, J.M. (1997) Cross-talk between receptor-mediated phospholipase C-b and D via protein kinase C as intracellular signal possibly leading to hypertrophy in serum-free cultured cardiomyocytes. J. Mol. Cell. Cardiol. 29, 2545-2559.
85. 38 mitogen-activated protein kinase pathway in neonatal rat ventricular myocytes by the G protein-coupled receptor agonists, endothelin-1 and phenylephrine. A role in cardiac myocyte hypertrophy? J. Cell Biol. 142, 523-535.
86. 2-adrenoceptor. J. Biol. Chem. 275, 21773-21779.
87. 2-adrenergic signal transduction. Circ. Res. 85, 1092-1100.
88. Holmer, S.R., Stevens, S. & Homcy, C.J. (1989) Tissue- and species-specific expression of inhibitory guanine nucleotide-binding proteins. Cloning of a full-length complementary DNA from canine heart. Circ. Res. 65, 1136-1140.
89. βγ subunits. FASEB. J. 12, 1019-1025.
90. Cooper, D.M.F., Mons, N. & Karpen, J.W. (1995) Adenylyl cyclases and the interaction between calcium and cAMP signalling. Nature 374, 421-424.
91. Iwami, G., Kawabe, J., Ebina, T., Cannon, P.J., Homcy, C.J. & Ishikawa, Y. (1995) Regulation of adenylyl cyclase by protein kinase A. J. Biol. Chem. 270, 12481-12484.
92. Widera, W., Kokot, F. & Wiecek, A. (1992) Do opioid receptors participate in the regulation of atrial natriuretic peptide (ANP) secretion in hypertensive patients? Clin. Nephrol. 38, 209-213.
93. Lechat, P. (1998) β-Blocker treatment in heart failure. Role of heart rate reduction. Basic. Res. Cardiol. 93, 148-155.
94. Sanders, L., Lynham, J.A., Bond, B., del Monte, F., Harding, S.E. & Kaumann, A.J. (1995) Sensitization of human atrial 5-HT4 receptors by chronic β-blocker treatment. Circulation 92, 2526-2539.
95. Svanegaard, J., Johansen, J.B., Thayssen, P. & Haghfelt, T. (1993) Neurohormonal systems during progression of heart failure: a review. Cardiology 83, 21-29.
96. Middlekauff, H.R. & Mark, A.L. (1998) The treatment of heart failure: the role of neurohumoral activation. Intern. Med. 37, 112-122.
97. Horn, E.M., Corwin, S.J., Steinberg, S.F., Chow, Y.K., Neuberg, G.W., Cannon, P.J. & Powers, E.R. (1988) Reduced lymphocyte stimulatory guanine nucleotide regulatory proteins and β-adrenergic receptors in congestive heart failure and reversal with angiotensin converting enzyme inhibitor therapy. Circulation 78, 1373-1379.
98. Saijonmaa, O. & Fyhrquist, F. (1998) Upregulation of angiotensin converting enzyme by atrial natriuretic peptide and cyclic GMP in human endothelial cells. Cardiovasc. Res. 40, 206-210.
99. Maisel, A.S., Phillips, C., Michel, M.C., Ziegler, M.G. & Carter, S.M. (1989) Regulation of cardiac β-adrenergic receptors by captopril. Implications for congestive heart failure. Circulation 80, 669-675.
100. Gilbert, W.M., Sandoval, A., Larabee, P., Renlund, D.G., O'Connel, J.B. & Bristow, M.R. (1993) Lisinopril lowers cardiac adrenergic drive and increases β-receptor density in the failing human heart. Circulation 88, 472-480.
101. Yonemochi, H., Saikawa, T., Yasunaga, S., Iwao, T., Takakura, T., Nakagawa, M., Sakata, T. & Ito, M. (1997) Angiotensin-converting enzyme inhibitor up-regulates cardiac β-adrenergic receptors in cultured neonatal rat myocytes. Jpn. Circ. J. 61, 170-179.
102. Böhm, M., Zolk, O., Flesch, M., Schiffer, F., Schnabel, P., Stasch, J.P. & Knorr, A. (1998) Effects of angiotensin II type 1 receptor blockade and angiotensin-converting enzyme inhibition on cardiac β-adrenergic signal transduction. Hypertension 31, 747-754.
103. Yonemochi, H., Yasunaga, S., Teshima, Y., Iwao, T., Akiyoshi, K., Nakagawa, M., Saikawa, T. & Ito, M. (1998) Mechanism of β-adrenergic receptor upregulation induced by ACE inhibition in cultured neonatal rat cardiac myocytes: roles of bradykinin and protein kinase C. Circulation 97, 2268-2273.
104. Kjaer, A. & Hesse, B. (2001) Heart failure and neuroendocrine activation: diagnostic, prognostic and therapeutic perspectives. Clin. Physiol. 21, 661-672.
105. Galal, O., Dzimiri, N., Moorji, A., Bakr, S. & Almotrefi, A.A. (1996) Sympathetic activity in children undergoing balloon valvuloplasty of pulmonary stenosis. Paediatr. Res. 39, 774-778.
106. Galal, O., Kalloghlian, A., Pittappilly, B.M. & Dzimiri, N. (1999) Phentolamine improves clinical outcome after balloon valvuloplasty in neonates with severe pulmonary stenosis. Cardiol. Young 9, 127-128.